Caredx Stock Price, News & Analysis

CareDx, Inc. (Nasdaq: CDNA) has announced the pricing of a public offering of 3,906,250 shares at $32.00 per share, aiming for gross proceeds of $125 million. The offering includes a 30-day option for underwriters to purchase an additional 585,937 shares. Expected to close around June 15, 2020, proceeds will support working capital and corporate purposes. The offering is registered under Form S-3ASR with the SEC. Goldman Sachs & Co. LLC and Jefferies LLC are leading the offering.

CareDx, Inc. (Nasdaq: CDNA) announced plans for an underwritten public offering of up to $100 million in its common stock. The company may grant underwriters a 30-day option to purchase an additional $15 million in shares. Proceeds will be used for working capital and general corporate purposes. The offering is contingent on market conditions and is being managed by Goldman Sachs & Co. LLC and Jefferies LLC. The offering is registered under a previously filed shelf registration statement with the SEC, and a preliminary prospectus will be available shortly.

CareDx, Inc. (Nasdaq: CDNA) announced an update regarding its 2020 Annual Meeting of Stockholders, which will now take place in a virtual format only due to COVID-19 restrictions. The meeting is scheduled for June 17, 2020, at 10:00 a.m. Pacific Time, and will cover the same agenda as previously communicated. Stockholders can still vote prior to the meeting using previously issued proxy materials. Instructions for attending the virtual meeting are provided, requiring a control number for stockholders, while guests can join with just their name and email.

CareDx, a precision medicine company focused on transplant patient solutions, announced its participation in the Goldman Sachs Global Healthcare Conference. The management will engage in a fireside chat on June 9, 2020, at 11:20 AM EDT. Interested stakeholders can access a live webcast through the company’s website. CareDx specializes in products and services that enhance the pre- and post-transplant experience, providing genomics-based information vital for transplant patients.

CareDx, Inc. (Nasdaq: CDNA) announced its participation in the Jefferies Virtual Healthcare Conference on June 3, 2020, at 11:00 AM EDT. The company, recognized for its precision medicine solutions for transplant patients, will provide a live webcast of its presentation available on its investor website. CareDx focuses on developing and commercializing high-value healthcare solutions and offers a range of products and services to support transplant patients and their caregivers.

CareDx, Inc. (Nasdaq: CDNA) has announced receiving CE mark approval for its AlloSeq Tx 17 technology, enhancing its availability for transplant patients, laboratories, and clinicians globally. This state-of-the-art solution offers superior donor organ matching and eliminates PCR disadvantages, improving workflow in Histocompatibility & Immunogenetics labs. Launched in September 2019, AlloSeq Tx 17 utilizes next-generation Hybrid Capture technology for HLA testing. CareDx aims to enhance patient care with genomics-based information, reinforcing its leadership in precision medicine for transplant solutions.

CareDx, Inc. (Nasdaq: CDNA) has formed a strategic alliance with Weill Cornell Medicine to become the exclusive partner for the development and commercialization of UroMap, a urine-based gene-expression test aimed at detecting acute cellular rejection in kidney transplant recipients. UroMap demonstrates high accuracy in identifying rejection episodes and may predict future occurrences. This collaboration enhances CareDx's portfolio of kidney transplant solutions, including AlloSure® and KidneyCare™. The exclusive rights for UroMap were secured through a license agreement with Cornell University.